Cefuroxime is a second generation cephalosporin antibiotic used to treat various bacterial infections. It is administered orally or intravenously and is absorbed with good bioavailability. The drug works by inhibiting bacterial cell wall synthesis, which leads to cell lysis and death. Its active moiety, the hydrolyzed form Cefuroxime axetil, releases Cefuroxime that binds to penicillin binding proteins. Binding to these proteins prevents the cross linking of peptidoglycan strands in the bacterial cell wall. This disruption weakens the wall making it vulnerable to osmotic pressure and immune defenses. As a result the medication helps clear infections of the respiratory tract, urinary tract, and skin. It does not affect viral infections and is generally well tolerated when used appropriately.

Cefuroxime is a second-generation cephalosporin antibiotic used to treat a variety of bacterial infections. It works by inhibiting the synthesis of bacterial cell walls through binding to specific penicillin-binding proteins. This interaction prevents the cross-linking of peptidoglycan strands, leading to weakened cell membranes and bacterial lysis. The drug is absorbed well after oral administration and reaches therapeutic concentrations in many tissues. Its chemical structure provides a broader activity spectrum than first-generation cephalosporins, covering many gram-positive and gram-negative organisms. By targeting the bacterial cell wall, Cefuroxime ultimately clears the infection and reduces inflammation. This mechanism of action differentiates it from other antibiotic classes that interfere with protein synthesis or nucleic acid metabolism.

Cefuroxime may cause mild nausea in some patients. It can also lead to diarrhea which is usually non-inflammatory. Skin reactions such as rash or itching are occasionally reported. Some individuals experience headaches or dizziness while taking the medication. Abdominal discomfort or mild pain may occur during treatment. These effects are generally transient and resolve without specific intervention.

Cefuroxime commonly causes gastrointestinal symptoms such as nausea and diarrhea. Headache and mild dizziness are also reported frequently. Skin reactions including rash and occasional itching may occur. Some patients experience abdominal discomfort or mild cramping. Elevated liver enzyme levels have been observed in a small proportion of cases. Allergic responses such as hives or swelling are rare but can develop.